Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

12.20USD
22 Nov 2017
Change (% chg)

$-0.20 (-1.61%)
Prev Close
$12.40
Open
$12.44
Day's High
$12.61
Day's Low
$12.11
Volume
146,238
Avg. Vol
224,332
52-wk High
$27.78
52-wk Low
$4.84

Chart for

About

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $517.20
Shares Outstanding(Mil.): 42.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.94 15.47
EPS (TTM): -- -- --
ROI: -- -10.73 11.81
ROE: -- -36.69 15.76

BRIEF-Achaogen reports Q3 loss per share $0.85

* Achaogen reports third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Achaogen submits Plazomicin new drug application to FDA

* Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections

Oct 26 2017

BRIEF-Achaogen awarded up to $18 million contract by BARDA

* Achaogen awarded up to $18 million contract by BARDA to support development of orally-administered antibacterial candidate C-Scape

Sep 28 2017

BRIEF-Achaogen reports Q2 loss per share $0.78

* Achaogen reports second quarter 2017 financial results and provides corporate update

Aug 03 2017

BRIEF-Point72 Asset Management reports 5.5 pct passive stake in Achaogen

* Point72 Asset Management Lp reports 5.5 percent passive stake in Achaogen Inc as of july 25 - sec filing Source text - http://bit.ly/2vK96pV Further company coverage:

Jul 26 2017

BRIEF-Achaogen says board increased size from nine directors to ten directors

* Achaogen says on July 11, in connection with Karen Bernstein's appointment, board increased size from nine directors to ten directors - SEC filing Source: (http://bit.ly/2vifzY4) Further company coverage:

Jul 13 2017

BRIEF-Achaogen starts C-Scape clinical development program with phase 1 study of orally-administered antibacterial candidate

* Initiates c-scape clinical development program with phase 1 study of orally-administered antibacterial candidate

Jun 01 2017

BRIEF-Achaogen announces pricing of public offering of common stock

* Achaogen announces pricing of public offering of common stock

May 25 2017

Earnings vs. Estimates